Loading
A phase 3 trial of UGN-102 in bladder & urothelial cancer, run by UroGen Pharma Ltd., active and no longer recruiting.
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT05243550 by UroGen Pharma Ltd., with 240 participants enrolled, started 2022-03-01 and due to reach its primary completion in 2023-04-26. Interventions recorded: UGN-102. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
240 enrolled.
95% CI 70.8 to 81.9; Figures from the ClinicalTrials.gov results section (first posted 2024-11-04), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Complete Response Rate (CRR)primary | UGN-102 | 240 | 76.7% | - | - | link |
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares UroGen Pharma, Bladder & urothelial cancer and the tag pipeline.
Shares UroGen Pharma, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.